• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.28
  • VXN 19.85
  • VXO 16.61
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
()
Last Trade Dividend/Share PE Ratio
Date Dividend Yield Return on Assets
Change ExDividend Date Return on Capital
Bid Latest EPS Price/Sale
Ask LatestEPS Date Price to Book
Volume EPS ttm Institutional %
Avg Volume Shares Outstanding Insider %
Open Float Short Ratio
Prev Close Return On Equity 5 Year Change %
High Consensus EPS 2 Year Change %
Low No. of Estimate 1 Year Change %
52 Week High EPS Surprise $ YTD Change %
52 Week Low EPS Surprise Percent 6 Month Change %
52 Week Change EBITDA 3 Month Change %
50 Day MA Revenue 1 Month Change %
200 Day MA Gross Profit 5 Day Change %
Market Cap Cash 30 Day Change %
Beta Debt Stock Exchange
Sector Revenue Per Share Short Interest
Short Date Revenue Per Employee Short Ratio
Data courtesy of IEX
Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices in Canada, the United States, and Europe. The company?s products include AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer?s disease; and NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. Its products under development comprise NX-1207, which is in Phase III clinical trials for the treatment of benign prostatic hyperplasia; and NX-1207, which is ready for human clinical trials for the treatment of hepatocellular carcinoma and localized prostate cancer. The company?s products in the preclinical stage comprise NXC-4720, an antibacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, and for the treatment of urinary tract and other bacterial infections in humans; NXB-4221 for the treatment of difficult chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. It is also developing therapeutics for Alzheimer?s disease; drugs for the treatment of Alzheimer?s disease that target spherons; and therapeutic products for oncological indications, as well as holds various diagnostic markers and technologies, including a patented platform for point-of-care testing. Nymox Pharmaceutical was founded in 1989 and is based in St. Laurent, Canada.